Photo of Fred Lublin

Fred Lublin

  • PROFESSOR Neurology
Print ProfilePrint Profile



  • Neurology, American Board of Psychiatry and Neurology

Clinical Focus


  • MD, Jefferson Medical College

  • Residency, Internal Medicine
    Bronx Municipal Hospital Center

  • Residency, Neurology
    New York Hospital


    Fred D. Lublin, MD is the Saunders Family Professor of Neurology and the Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai Medical Center. He is an internationally renowned authority on the scientific and clinical aspects of MS; he is also one of the foremost authorities regarding experimental therapies.

    Dr. Lublin is a neuroimmunologist and as such has a special interest in immune functions and abnormalities that affect the nervous system. He has been involved in both and clinical and basic science research. 

    Dr. Lublin was chairman of the National Multiple Sclerosis Society (USA) advisory committee on clinical trials of new MS drugs; and he is currently chair of the Clinical Advisory Committee of the New York City Chapter of the National MS Society.  

    Dr. Lublin is a member of many professional societies and advisory boards. He has published numerous scientific articles and has served as a consultant to the NIH, as well as to pharmaceutical and biotech companies in all phases of drug development, and in preparation for drug presentation to the FDA and its advisory panels.

    Dr. Lublin received his medical degree at Jefferson Medical College, Philadelphia, PA.  He completed his internship in Internal Medicine at the Bronx Municipal Hospital, Albert Einstein Medical Center, and his residency at the New York Hospital, Cornell Medical Center.


  • 2013 -
    Award of Appreciation for Outstanding Academic Teaching
    Icahn School of Medicine at Mount Sinai

  • 2001 -
    Attending of the Year Award
    Mount Sinai Medical Center Neurology Residents

  • 2000 - Present
    Chairman, Research Programs Advisory Committee
    National Multiple Sclerosis Society

  • 1999 -
    Hope Award
    National Multiple Sclerosis Society, Delaware Valley Chapter

  • 1999 -
    McEwan Visiting Professorship & Lecture in Neurology
    University of Toronto

  • 1996 -
    Milestone Award
    National Multiple Sclerosis Society, Delaware Valley Chapter


Goodman AD, Bethoux F, Brown TR, Schapiro RT, Cohen R, Marinucci LN, Henney HR, Blight AR. Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials. Multiple sclerosis (Houndmills, Basingstoke, England) 2015 Jan;.

Weisfeld-Adams JD, Katz Sand IB, Honce JM, Lublin FD. Differential diagnosis of Mendelian and mitochondrial disorders in patients with suspected multiple sclerosis. Brain : a journal of neurology 2015 Mar; 138(Pt 3).

Vidaurre OG, Haines JD, Katz Sand I, Adula KP, Huynh JL, McGraw CA, Zhang F, Varghese M, Sotirchos E, Bhargava P, Bandaru VV, Pasinetti G, Zhang W, Inglese M, Calabresi PA, Wu G, Miller AE, Haughey NJ, Lublin FD, Casaccia P. Cerebrospinal fluid ceramides from patients with multiple sclerosis impair neuronal bioenergetics. Brain : a journal of neurology 2014 Aug; 137(Pt 8).

Datta S, Staewen TD, Cofield SS, Cutter GR, Lublin FD, Wolinsky JS, Narayana PA. Regional gray matter atrophy in relapsing remitting multiple sclerosis: baseline analysis of multi-center data. Multiple sclerosis and related disorders 2015 Mar; 4(2).

Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, Vollmer T, Agius MA, Kappos L, Stites T, Li B, Cappiello L, von Rosenstiel P, Lublin FD. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet. Neurology 2014 Jun; 13(6).

Oynhausen S, Alcauskas M, Hannigan C, Bencosme Y, Müller M, Lublin F, Krieger S. Emergency medical care of multiple sclerosis patients: primary data from the mount sinai resource utilization in multiple sclerosis project. Journal of clinical neurology (Seoul, Korea) 2014 Jul; 10(3).

Lublin FD. New multiple sclerosis phenotypic classification. European neurology 2014; 72 Suppl 1.

Pandey KS, Lublin FD, Miller AE, Krieger SC. Clinical Course in Multiple Sclerosis Patients Presenting with a History of Progressive Disease. Multiple Sclerosis and Related Disorders 2014;(3): 67-71.

Lublin FD, Bowen J, Huddlestone J, Kremenchutzky J. Human Placenta-Derived Cells (PDA-001) for the Treatment of Adults with Multiple Sclerosis: A Randomized, Placebo-Controlled, Multiple-Dose Study. Multiple Sclerosis and Related Disorders 2014 September;.

Lublin FD, Cutter G, Giovannoni G, Pace a. Natalizumab Reduces Relapse Clinical Severity and Improves Relapse Recovery in MS. Multiple Sclerosis and Related Disorders 2014 September;.

Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014 Jul; 83(3).

Lublin FD, Cofield SS, Cutter GR, Conwit R, Narayana PA, Nelson F, Salter AR, Gustafson T, Wolinsky JS. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Annals of neurology 2013 Mar; 73(3).

Lublin FD. MS as a gateway disease. Journal of the neurological sciences 2013 Oct; 333(1-2).

O'Connor PW, Lublin FD, Wolinsky JS, Confavreux C, Comi G, Freedman MS, Olsson TP, Miller AE, Dive-Pouletty C, Bégo-Le-Bagousse G, Kappos L. Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use. Journal of neurology 2013 Oct; 260(10).

Narayana PA, Govindarajan KA, Goel P, Datta S, Lincoln JA, Cofield SS, Cutter GR, Lublin FD, Wolinsky JS. Regional cortical thickness in relapsing remitting multiple sclerosis: A multi-center study. NeuroImage. Clinical 2012; 2.

Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of neurology 2011 Feb; 69(2).

Lublin FD, Bowen JD, Huddlestone J, Kremenchutzky M, Carpenter A, Corboy JR, Freedman MS, Krupp L, Paulo C, Hariri RJ, Fischkoff SA. Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study. Multiple sclerosis and related disorders 2014 Nov; 3(6).

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Lublin during 2015 and/or 2016. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Scientific Advisory Board:

  • Acorda Therapeutics Inc.; Actelion Pharmaceuticals Ltd.; Bayer; Biogen Idec; EMD Serono, Inc. (Merck & Co., Inc.); F. Hoffman-La Roche Ltd.; Facilitate, LTD; Forward Pharma; MedImmune, LLC; Novartis; Osmotica Pharmaceutical Corp.; Questcor Pharmaceuticals, Inc.; Receptos Inc.; Revalesio Corporation; Teva Pharmaceutical Industries Ltd.; XenoPort, Inc.; sanofi-aventis; to-BBB

Other Activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership.

  • Gerson Lehrman Group

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Insurance Information

Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).

Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.

Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.

Edit profile in Sinai Central


Faculty Practice Associates Floor 1st Floor Room MS Center
5 East 98th Street
New York, NY 10029


Annenberg Building
1468 Madison Avenue
New York, NY 10029

Tel: 212-241-6854
Fax: 212-423-0440

5 East 98th Street
Box 1138
New York, NY 10029

Tel: 212-241-6854
Fax: 212-241-5333
Get Directions

Office Hours:
  • Wednesday 9:00am - 5:00pm
  • Thursday 9:30am - 5:00pm
Insurance Plans
  • Medicaid
  • Medicare
  • United Health Care - Mount Sinai Top Tier
Payment Methods
  • Master Card
  • Visa
  • American Express
  • Personal Check
  • Cash